Whatever the demands of international regulators, it is public expectations that will ultimately dictate the need for life sciences companies to prepare complete and accurate product data that patients and healthcare providers can scrutinize on demand.
Each year, more than 250,000 Americans die from the common and deadly condition.
For founders and owners of privately held medical product businesses, the amount of private investment dollars available is significant.
Medtech decision makers must accurately predict future trends in order to chart the best future directions and identify the most advantageous areas for business investment.
There are several critical questions that your internal team should be ready to address when preparing product portfolios and seeking out a CRO.
Artificial intelligence and machine learning technologies have significant potential, but regulatory hurdles may stand in their way.
Health technology developers need to prioritize security from the moment a device or platform is first incepted.
Class I device manufacturers need to keep on top of new classification rules to avoid loss of market share under the close approaching EU MDR deadline.
A timely step toward ensuring patient safety through data-driven product development.
The technology can prevent ongoing tissue damage and degeneration before an issue becomes too large to fix.